AngioDynamics, Inc. (NASDAQ:ANGO) SVP Warren Nighan, Jr. Sells 4,060 Shares

AngioDynamics, Inc. (NASDAQ:ANGO) SVP Warren Nighan, Jr. sold 4,060 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the transaction, the senior vice president now directly owns 41,817 shares of the company’s stock, valued at approximately $514,767.27. This trade represents a 8.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

AngioDynamics Trading Down 2.7 %

Shares of ANGO opened at $12.43 on Monday. The company has a market cap of $502.99 million, a price-to-earnings ratio of -2.21 and a beta of 0.59. The business’s fifty day simple moving average is $8.75 and its two-hundred day simple moving average is $7.68. AngioDynamics, Inc. has a 12 month low of $5.26 and a 12 month high of $13.13.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The company had revenue of $72.90 million for the quarter, compared to analysts’ expectations of $70.93 million. During the same period last year, the firm posted ($0.05) earnings per share. AngioDynamics’s revenue was down .1% compared to the same quarter last year. As a group, research analysts forecast that AngioDynamics, Inc. will post -0.36 EPS for the current year.

Analysts Set New Price Targets

ANGO has been the subject of several analyst reports. HC Wainwright raised their price target on AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a report on Friday, January 10th. Canaccord Genuity Group reduced their price objective on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, October 4th.

Institutional Trading of AngioDynamics

Large investors have recently made changes to their positions in the stock. Quarry LP lifted its position in AngioDynamics by 75.1% during the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 2,594 shares during the period. CWM LLC raised its stake in AngioDynamics by 981.3% during the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock valued at $76,000 after buying an additional 8,832 shares during the last quarter. Mackenzie Financial Corp bought a new position in shares of AngioDynamics during the 2nd quarter valued at $80,000. Wealth Enhancement Advisory Services LLC purchased a new position in shares of AngioDynamics in the 3rd quarter worth $86,000. Finally, AE Wealth Management LLC bought a new stake in shares of AngioDynamics in the second quarter worth $87,000. 89.43% of the stock is currently owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.